Hepatocellular Carcinoma (HCC) is a complex disease and it is widely accepted that a multidisciplinary team approach is the best to tailor a personalised management. This generally depends on multiple factors such as tumour burden, extent of hepatic dysfunction, morbid medical conditions and patient preference. Treatment options range from curative surgery for resectable disease, to locoregional therapy such as radiofrequency ablation, or palliative options which include chemotherapy, immunotherapy, transarterial chemoembolisation and Y90 hepatic radioembolisation.
Subspeciality experts from surgery, medical oncology, interventional radiology and nuclear medicine will provide updates on the treatment options and highlight research findings from phase 3 clinical trials such as Checkmate 040, SIRveNIB (AHCC 06) and ongoing PLANet AHCC07 trials. The speakers from oncologic imaging radiology will also share their experiences in employing artificial intelligence to identify radiomics signature of HCC.
